A recent study that was published in the New England Journal of Medicine (and also funded by Novo Nordisk) evaluated about 10,000 participants who had type 2 diabetes and also atherosclerosis or chronic kidney disease, or both
Retrieved from Baystate Health
This information can support more informed discussions with your provider about whether your metabolic profile favors aggressive fasting or whether standard GLP-1 use alone meets your goals
By improving insulin sensitivity, blood glucose control, blood pressure and overall metabolic health, GLP-1 agonists may help address several underlying drivers of kidney stone disease
A slower metabolic rate generates less internal warmth, which some patients perceive as increased cold sensitivity or chilliness
When blood glucose remains persistently high, as it does in poorly managed diabetes, it causes microvascular damage throughout the body